Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 15364 participants.

Also called NCT07626411

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 15,364 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07626411
  • EU CT 2025-521617-97-00
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Canada, Japan (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07626411. Randomized; quadruple masking; primary purpose prevention. Start 2026-08-10 (actual); primary completion 2029-09-11 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation
Acronym
ROXI-EVEREST
Condition
Atrial Fibrillation (AF)
Intervention (Drug)
REGN7508
Intervention (Drug)
Apixaban
Intervention (Drug)
Placebo
Lead sponsor
Regeneron Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct07626411
Content hash
29eb452677ab9ca6b1894a9c3201cd346c08bf605fbd86f48a3ddd1280af951c